Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical : also well on track in second quarter

08/06/2020 | 02:15am EDT

DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Half Year Results/Quarter Results
CompuGroup Medical also well on track in second quarter

06.08.2020 / 08:10
The issuer is solely responsible for the content of this announcement.

- 6% organic growth yoy excluding Telematics Infrastructure

- Significant increase in recurring revenues across all segments

- Higher revenues expected in second half 2020 due to approval of e-health connector

- Full year guidance raised

- Additional headroom for growth due to share placement

Koblenz. CompuGroup Medical (CGM) is looking back once again at a solid quarter. Although the second quarter of 2020 was significantly affected by the economic impact of the COVID-19 pandemic, Koblenz based CompuGroup Medical, one of the largest providers of e-Health solutions worldwide, is well on track financially. CGM is expecting continued positive business performance due to increasing digitizing in healthcare and corresponding measures by the government and the economy. Against this background, CGM is well set to continue the current investment and growth path, supported by a share placement at the end of June resulting in gross proceeds of approximately EUR 341 million.

Frank Gotthardt, founder and CEO of CompuGroup Medical, "Our company showed its strong resilience and solid business model in the face of uncertainties of a pandemic in the first and especially in the second quarter. We have seen many people becoming directly aware of the benefits of digitization in healthcare during this time. In the third quarter, healthcare professionals and patients will be able to benefit even more from the opportunities of digital communication. Since the CGM e-health connector KoCoBox MED+ has been approved and is now being rolled out, emergency data and electronic medication plans on a health card will become normal along with digital communication between service providers. All of this encourages us to continue with our consistent growth course from past years."

Group: Stable performance and positive outlook

Overall, CGM was fully on track in the second quarter and generated group revenues of EUR 179.9 million. Adjusted EBITDA grew by 1% to EUR 44.6 million year-on-year. The prior year quarter had been characterized by high installation revenues for the Telematics Infrastructure (TI) in German doctors' practices with revenues of EUR 186.6 million. Without these TI one-time revenues, group revenues grew organically by 6% in spite of the effects and uncertainties from COVID-19, and recurring revenues significantly increased by 10%. Due to the July 2020 approval of KoCoBox MED+ as an e-health connector, CGM expects good one-time revenues in the second half of the year from the software upgrade in more than 55,000 practices. In addition, the rollout of the Telematics Infrastructure can now begin in pharmacies.

Adjusted Group EBITDA increased from EUR 44.3 million (pro-forma) to EUR 44.6 million in the second quarter of 2020. The operating margin is still at a high level with 25% (previous year: adjusted 24%). CGM generated a consolidated profit of EUR 16.3 million in the second quarter (previous year: EUR 14.2 million). Adjusted earnings per share (diluted) were EUR 0.38, exactly at the previous year's level of EUR 0.38 in spite of the increased number of shares outstanding following the share placement.

Capital expenditures stood at EUR 13.5 million, slightly below the previous year (EUR 14.3 million). Operating cash flow in the reporting period was characterized by a decrease in payables and an increase in inventory and income tax receivables. Adjusted free cash flow was at EUR -0.8 million (previous year EUR 23.5 million), which is primarily due to high, one-off payments from TI connections in the previous year. Net debt as of June 30, 2020 was at EUR 123.2 million and thus EUR 343.7 million lower versus year-end 2019 (EUR 466.9 million). As of June 30, 2020, the company employed 5,826 people, 369 more than at the end of the previous year quarter. Including the successfully concluded takeover of the Cerner portfolio, which took place after the reporting date of June 30, 2020, the company employs more than 6,100 people.

CGM is increasing its guidance for the full year. Including the acquisition of parts of the Cerner portfolio in Germany and Spain, which was finalized on July 1, revenues are now expected in the range of EUR 820 million to EUR 860 million. Guidance for adjusted EBITDA is also raised to a new range of EUR 205 million to EUR 220 million.

Segments: All segments are growing recurring revenue

Revenues in the Ambulatory Information Systems segment were down 9% year-on-year because of the especially high sales from the TI rollout in the previous year quarter as a one-off effect. Recurring revenues significantly increased year-on-year by 8% to EUR 81.4 million, representing 77% of total segment revenues. Organic revenue growth excluding TI stood at 7% in the second quarter of 2020.

Business in the Pharmacy Information Systems (PCS) segment was positively affected in the second quarter by successful sales of additional modules for cashpoints in German pharmacies. Revenues increased by 6% to EUR 29.6 million (previous year: EUR 27.8 million). Recurring revenues increased by almost 9% year-on-year and reached EUR 18.9 million. The share of recurring revenues increased by one percentage point to 64% of the segment's revenues. Revenues also increased organically by approximately 6%. Adjusted EBITDA was EUR 8.0 million (previous year: EUR 6.0 million) with an operating margin of 27% (previous year: 21%).

The Hospital Information Systems (HIS) segment increased revenues in the second quarter by 4% to EUR 33.4 million (previous year: EUR 32.3 million). Recurring revenues increased by 12% to EUR 21.8 million. Thus, the portion of recurring revenue in the segment's revenues increased from 60% to 65%. Adjusted EBITDA was EUR 5.5 million after EUR 1.6 million in the previous year quarter, which is an increase of the operating margin to 16% (previous year: 5%).

The Consumer & Health Management Information Systems (CHS) segment increased revenues by 6% to EUR 10.6 million (previous year: EUR 9.9 million), which mainly resulted from the CGM LIFE division that significantly increased its business with private health insurance companies. Organic growth was also 6%. Adjusted EBITDA of EUR 1.4 million was slightly under the previous year quarter (EUR 1.5 million) due to increased development costs.

The complete half year report is available on the company's website at www.cgm.com under Investor Relations.

About CompuGroup Medical SE & Co. KGaA
CompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.5 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 6,100 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

Contact for media representatives:
Michael Franz
Head of Brand Communication
P +49 (0) 261 8000-6100
F +49 (0) 261 8000-3100
E-mail: press@cgm.com

Contact for analysts and investors:
Claudia Thomé
Head of Investor Relations
P +49 (0) 261 8000-7030
F +49 (0) 261 8000-3200
E-mail: claudia.thome@cgm.com

06.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Phone: +49 (0)261 8000 6200
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1111395

End of News DGAP News Service

1111395  06.08.2020 


ę EQS 2020
09:24aCOMPUGROUP MEDICAL : Deutsche Bank gives a Buy rating
07/22COMPUGROUP MEDICAL : KoCoBox MED+ obtains approval as an electronic health recor..
07/22CompuGroup Medical Receives Kocobox MED+ Obtains Approval as an Electronic He..
07/19COMPUGROUP MEDICAL SE & CO. KGAA : Preliminary announcement of the publication o..
06/17COMPUGROUP MEDICAL SE & CO. KGAA : Release according to Article 40, Section 1 of..
06/14COMPUGROUP MEDICAL : Company Presentation June
06/02COMPUGROUP MEDICAL : Receives a Sell rating from Baader Bank
06/01CompuGroup Medical SE & Co. KGaA acquired Visus Health It Gmbh.
05/21COMPUGROUP MEDICAL : Receives a Sell rating from Baader Bank
05/20COMPUGROUP MEDICAL SE & CO. KGAA : Ex-dividend day for final dividend
More news
Sales 2021 1 019 M 1 200 M 1 200 M
Net income 2021 79,5 M 93,6 M 93,6 M
Net Debt 2021 430 M 507 M 507 M
P/E ratio 2021 46,9x
Yield 2021 0,72%
Capitalization 3 677 M 4 326 M 4 332 M
EV / Sales 2021 4,03x
EV / Sales 2022 3,77x
Nbr of Employees 7 534
Free-Float 48,9%
Duration : Period :
CompuGroup Medical Societas Europaea Technical Analysis Chart | COP | DE0005437305 | MarketScreener
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 69,25 €
Average target price 80,19 €
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Dirk Woessner Chairman-Management Board & CEO
Michael Rauch Chief Financial Officer
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Hannes Reichl Managing Director-Clinical & Social Care
Sector and Competitors
1st jan.Capi. (M$)
SAP SE9.87%165 786
INTUIT INC.39.12%132 829
SERVICENOW, INC.6.49%107 607
DOCUSIGN, INC.38.78%54 398